| Literature DB >> 21529366 |
Anuj Sharma1, Manish Bhomia, Shelley P Honnold, Radha K Maheshwari.
Abstract
BACKGROUND: Neuroinvasion of Venezuelan equine encephalitis virus (VEEV) and subsequent initiation of inflammation in the brain plays a crucial role in the outcome of VEEV infection in mice. Adhesion molecules expressed on microvascular endothelial cells in the brain have been implicated in the modulation of the blood brain barrier (BBB) and inflammation in brain but their role in VEEV pathogenesis is not very well understood. In this study, we evaluated the expression of extracellular matrix and adhesion molecules genes in the brain of VEEV infected mice.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21529366 PMCID: PMC3113303 DOI: 10.1186/1743-422X-8-197
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Mouse extracellular matrix and adhesion molecules gene(s) differentially expressed by two fold in VEEV infected CD 1 mouse brain.
| 9 | NM_009851 | CD44 antigen (Cd44) | (A) | 5.24 (PI) ± 4.24 (0.37) | 16.35 (PI) ± 10.09 (0.20) | 34.83 (PI) ± 3.23 (0.0004) |
| 10 | NM_009864 | Cadherin 1 (Cdh1) | 3.97 ± 0.32 (0.0007) | 4.98 ± 3.37 (0.30) | 6.52 ± 5.23 (0.35) | 16.79 ± 1.57 (0.0005) |
| 14 | NM_009868 | Cadherin 5 (Cdh5) | (A) | 1.17 (PI) ± 0.17 (0.37) | 1.92 (PI) ± 0.59(0.19) | 9.57 (PI) ± 0.97 (0.0009) |
| 29 | NM_016919 | Procollagen, type V, alpha 3 (Col5a3) | 0.81 ± 0.15 (0.51) | 1.09 ± 0.19 (0.78) | 1.60 ± 0.67 (0.16) | 2.07 ± 0.31 (0.03) |
| 32 | NM_007739 | Procollagen, type VIII, alpha 1 (Col8a1) | 1.41 ± 0.49 (0.53) | 1.77 ± 1.31(0.27) | 1.18 ± 0.39 (0.70) | 0.80 ± 0.61 (0.65) |
| 34 | XM_488510/ | Mus musculus chondroitin sulfate proteoglycan 2(Cspg2)/Versican (Vcan) | 1.14 ± 0.40 (0.74) | 2.36 ± 0.80 (0.28) | 3.34 ± 1.13 (0.23) | 4.39 ± 1.83 (0.07) |
| 35 | NM_010217 | Connective tissue growth factor (Ctgf) | 0.88 ± 0.13 (0.38) | 0.91 ± 0.13 (0.52) | 0.83 ± 0.05 (0.24) | 0.45 ± 0.10 (0.01) |
| 38 | NM_009848 | Ectonucleoside triphosphate diphosphohydrolase 1(Entpd1) | (A) | (A) | (A) | 4.37 (PI) ± 1.41 (0.03) |
| 41 | NM_013500 | Hyaluronan and proteoglycan link protein 1 (Hapln1) | 0.67 (PI) ± 0.29 | 1.15 (PI) ± 0.13 (0.73) | (A) | (A) |
| 43 | NM_010493 | Intercellular adhesion molecule (Icam1) | 2.82 (PI) ± 1.32 (0.24) | 8.4 (PI) ± 3.00 (0.07) | 13.51 (PI) ± 6.24 (0.12) | 36.76 (PI) ± 4.81 (0.001) |
| 56 | NM_021334 | Integrin alpha × (Itgax) | (A) | (A) | 4.49 ± 1.12 (0.01) | 3.55 (PI) ± 0.89 (0.02) |
| 57 | NM_010578 | Integrin beta 1 (fibronectin receptor beta) (Itgb1) | 1.06 ± 0.48 (0.83) | 1.61 ± 0.35 (0.27) | 2.41 ± 0.56 (0.02) | 2.67 ± 0.39 (0.01) |
| 58 | NM_008404 | Integrin beta 2 (Itgb2) | (A) | (A) | (A) | 4.79 (PI) ± 0.27 (0.0.0001) |
| 59 | NM_016780 | Integrin beta 3 (Itgb3) | 1.36 (PI) ± 0.25 (0.59) | 2.32 (PI) ± 0.30 (0.10) | 3.37 (PI) ± 1.32 (0.03) | 3.06 (PI) ± 0.55 (0.01) |
| 63 | NM_013566 | Integrin beta 7 (Itgb7) | 0.83 ± 0.13 (0.50) | (A) | 3.40 ± 1.98 (0.27) | 7.84 (PI) ± 3.04 (0.04) |
| 96 | NM_011346 | Selectin, lymphocyte (Sell) | 2.67 (PI) ± 0.89 (0.33) | 10.06 (PI) ± 5.41 (0.08) | 20.37(PI) ± 11.02 (0.07) | 21.45 (PI) ± 5.60 (0.001) |
| 97 | NM_011347 | Selectin, platelet (Selp) | 12.66 (PI) ± 8.84 (0.26) | 32.57 (PI) ± 2.66 (0.0002) | 43.14 (PI) ± 5.70 (0.001) | 37.60 (PI) ± 4.37 (0.001) |
| 105 | NM_011581 | Thrombospondin 2 (Thbs2) | 1.17 ± 0.34 (0.58) | 1.60 ± 0.82 (0.44) | 2.87 ± 1.58 (0.40) | 4.02 ± 3.50 (0.39) |
| 107 | NM_011582 | Thrombospondin 4 (Thbs4) | 11.99 ± 3.25 (0.03) | 2.70 ± 1.19 (0.22) | 1.30 ± 0.30 (0.37) | (A) |
| 5 | NM_013906 | A disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 8 (Adamts8) | (A) | 2.44 (PI) ± 0.34 (0.01) | (A) | 2.78 (PI) ± 0.41 (0.01) |
| 16 | NM_007729 | Procollagen, type XI, alpha 1 (Col11a1) | (A) | 2.60 ± 1.61(0.37) | (A) | (A) |
| 77 | NM_008608 | Matrix metallopeptidase 14 (membrane-inserted) (Mmp14) | 0.51 ± 0.09 (0.05) | 1.07 ± 0.12 (0.76) | 1.32 ± 0.28 (0.11) | 1.24 ± 0.20 (0.17) |
| 78 | NM_008609 | Matrix metallopeptidase 15 (Mmp15) | (A) | (A) | 2.48 ± 1.48 (0.37) | (A) |
| 79 | NM_019724 | Matrix metallopeptidase 16 (Mmp16) | 0.49 ± 0.16 (0.09) | 1.62 ± 0.07 (0.22) | 0.68 ± 0.26 (.035) | 1.18 ± 0.32 (0.65) |
| 87 | NM_010809 | Matrix metallopeptidase 3 (Mmp3) | 4.60 (PI) ± 3.34 (0.34) | 29.25 (PI) ± 8.41 (0.03) | 48.06 (PI) ± 2.98 (0.00009) | 26.60 (PI) ± 5.76 (0.01) |
| 89 | NM_008611 | Matrix metallopeptidase 8 (Mmp8) | 1.21 ± 0.29 (0.46) | (A) | 6.15 ± 4.73 (0.38) | 22.59 (PI) ± 6.94 (0.05) |
| 101 | NM_009263 | Secreted phosphoprotein 1 (Spp1) | 1.00 ± 0.03 (0.99) | 0.67 ± 0.18 (0.12) | 0.63 ± 0.17 (0.12) | 0.50 ± 0.06 (0.01) |
| 103 | NM_009369 | Transforming growth factor, beta induced (Tgfbi) | 0.87 ± 0.10 (0.40) | 0.55 ± 0.19 (0.15) | 0.06 ± 0.04 (0.001) | 0.08 ± 0.06 (0.001) |
| 108 | NM_011593 | Tissue inhibitor of metalloproteinase 1 (Timp1) | (A) | 4.88 (PI) ± 2.38 (0.18) | 17.64 (PI) ± 5.88 (0.05) | 13.79 (PI) ± 1.36 (0.0007) |
| 112 | NM_011607 | Tenascin C (Tnc) | (A) | (A) | 0.49 ± 0.25 (0.37) | (A) |
Genes that are differentially expressed by ≥2.0 fold are represented. Values are represented at mean fold difference ± SEM (P-value). (A) = absent; PI = present in infection and; PC = present in saline control.
Figure 1ICAM-1 expression corresponds with perivascular cuffing, fibrinogen leakage, and the presence of VEEV in the brains of VEEV infected mice. (a) H&E staining of the brain of VEEV infected CD-1 mice exhibited prominent perivascular cuffs throughout the brain. (b) Endothelial cells are hypertrophied and exhibit positive immunoreactivity for ICAM-1. (c) Immunohistochemistry for fibrinogen demonstrated localized fibrinogen leakage around hypertrophied endothelial cells, indicating disruption of the BBB. (d) Extensive VEEV specific staining revealed numerous cells infected with VEEV around the affected vessels. (e) Perivascular cuffs were composed of moderate numbers of mononuclear cells, primarily lymphocytes and fewer monocytes which had transmigrated the endothelium and multifocally extended into the neuropil. (f) Neurons were primarily infected with VEEV; however, VEEV antigen was also localized in glia and fewer lymphocytes. (g) Vacuolation of the neuropil was observed around the affected vessels.
Figure 2Survival study in IKO mice. Representative of two separate survival studies done in IKO mice upon VEEV infection is shown here. Mice were observed twice a day for fourteen days pi for signs of clinical disease. There was a 20% reduction in mortality in IKO mice over their WT controls in both the studies.
Figure 3Inflammation in the brain of VEEV infected IKO and WT mice. (a) IKO 96 hr pi cerebrum, subventricular zone, H&E, 400X: There were low numbers of necrotic neurons, characterized by small amounts of karyorrhexis (arrows), when compared to the same region of the WT mice (b). (b) WT 96n hr pi, cerebrum, subventricular zone, H&E, 400X: There were high numbers of necrotic neurons, characterized by large amounts of karyorrhexis (arrows), when compared to the same region of IKO mice (a). (c) IKO 96 hr pi, brainstem, H&E, 400X: There was little to no endothelial swelling and no perivascular cuffing (arrows) compared to the WT mice (d). (d) WT 96 hr pi, brainstem, H&E, 400X: There was moderate endothelial swelling and mild perivascular cuffing (thick arrows) and rare necrotic cells (thin arrow) compared to the IKO mice (c). (e) IKO 96 hr pi, brain, thalamus, H&E, 400X: There was little to no endothelial swelling and no perivascular cuffing (arrows) compared to the WT mice (f). (f) WT 96 hr pi, brain, thalamus, H&E, 400X: There was moderate endothelial swelling and mild perivascular cuffing (thick arrow) and rare necrotic cells (thin arrows) compared to the IKO mice (e).
Differential gene expression in brains of VEEV infected ICAM-1 WT mice (n = 3) as compared to IKO mice (n = 3) at 96 hr pi.
| WT | ||||||
|---|---|---|---|---|---|---|
| 7 | NM_011332 | Ccl17 | Chemokine (C-C motif) ligand 17 (Ccl17) | 73.57 | (A) | P-IKO |
| 13 | NM_019577 | Ccl24 | Chemokine (C-C motif) ligand 24 (Ccl24) | (A) | 273.69 POR | P-WT |
| 22 | NM_009912 | Ccr1 | Chemokine (C-C motif) receptor 1 (Ccr1) | 132.24 ± (40.75) | 28.80 POR | 4.59 |
| 35 | NM_019494 | Cxcl11 | Chemokine (C-X-C motif) ligand 11 (Cxcl11) | 435.04 ± (167.36) | 690.98 ± (322.64) | 0.63 |
| 37 | NM_018866 | Cxcl13 | Chemokine (C-X-C motif) ligand 13 (Cxcl13) | 163.29 POR | 245.09 ± (156.61) PTwR | 0.67 |
| 49 | NM_008337 | Ifng | Interferon gamma (Ifng) | 211.35 ± (21.67) PTwR | 122.81 ± (12.68) PTwR | 1.72 |
| 51 | NM_010548 | Il10 | Interleukin 10 (Il10) | (A) | 57.40 ± (43.51) PTwR | P-WT |
| 68 | NM_008362 | Il1r1 | Interleukin 1 receptor, type I (Il1r1) | 119.93 POR | (A) | P-IKO |
| 69 | NM_010555 | Il1r2 | Interleukin 1 receptor, type II (Il1r2) | 287.27 POR | 172.19 ± (94.76) PTwR | 1.67 |
| 73 | NM_016971 | Il22 | Interleukin 22 (Il22) | (A) | 186.84 POR | P-WT |
| 74 | NM_008368 | Il2rb | Interleukin 2 receptor, beta chain (Il2rb) | 151.12 POR | 31.83 POR | 4.75 |
| 93 | NM_011101 | Prkca | Protein kinase C, alpha (Prkca) | 60.8 POR | (A) | P-IKO |
| 94 | NM_009007 | Rac1 | RAS-related C3 botulinum substrate 1 (Rac1) | 195.79 ± (6.81) PTwR | 105.57 ± (81.61) PTwR | 1.85 |
| 95 | NM_007926 | Scye1 | Small inducible cytokine subfamily E, member 1 (Scye1) | 385.53 ± (137.18) | 243.61 ± (159.47) | 1.58 |
| 96 | NM_009263 | Spp1 | Secreted phosphoprotein 1 (Spp1) | 693.01 ± (74.26) | 389.60 ± (127.58) | 1.78 |
| 104 | NM_133211 | Tlr7 | Toll-like receptor 7 (Tlr7) | 176.40 ± (87.47) PTwR | 35.74 ± (22.32) PTwR | 4.94 |
| 107 | NM_013693 | Tnf | Tumor necrosis factor (Tnf) | 74.90 ± (8.85) PTwR | 193.78 POR | 0.39 |
| 112 | NM_008510 | Xcl1 | Chemokine (C motif) ligand 1 (Xcl1) | 76.09 ± (42.81) PTwR | (A) | P-IKO |
Average expression values of gene are given. Where gene expression was detected in only one biological sample and not the replicates, the gene expression value is followed by POR (present in one replicate), similarly where the gene expression was detected in two biological replicates the gene expression value is followed by PTwR (present in two replicates). The fold expression values are derived by dividing average expression (or expression value from one or two replicates) of VEEV infected IKO samples with average expression (or expression value from one replicate) of VEEV infected ICAM WT samples and vice versa. PI = Expressed only in VEEV infected samples, PC = Expressed in uninfected saline control samples only, (A) = absent. Values are expressed as ± SEM.
Figure 4Inflammation was reduced in VEEV infected mice treated with naproxen or naproxen plus ribavirin. Animals were treated with naproxen (40 mg/kg/once a day) only or naproxen plus ribavirin (80 mg/kg/once a day) at the time of infection (1000 pfu of VEEV inoculated in left rear foot pad). Animals were monitored twice a day and clinical symptoms of disease were monitored for two weeks.
Figure 5Viral load in the brain of mice treated with naproxen and naproxen plus rivavirin. Animals were treated with naproxen and naproxen plus ribavirin as described in the text. Mice were sacrificed at each given time points (n = 5 each group) and brain tissues were evaluated for viral load by RT-PCR. Given is a representative picture of one of the set of the mice. (1) drug treated 120 hr pi; (2) untreated 120 hr pi; (3) drug treated 96 hr pi; (4) untreated 96 hr pi; (5) drug treated 72 hr pi; (6) untreated 72 hr pi; (7) drug treated 48 hr pi; and (8) untreated 48 hr pi.